Good MorningThe market heaved a sigh of relief after Fed president Raphael Bostic said the committee could probably stick with quarter-point interest rate hikes. The news is contrary to a renewed belief the Fed could increase the pace to 50 bps per meeting, but investors should not be sanguine. The news does not suggest that inflation has been tamed or the Fed was anywhere near through with raising rates.
Regardless of the Fed's next move, the outlook for S&P 500 earnings continues to decline, and that is a weight the market can't bear forever. Sooner or later, the market will give up all hope for earnings growth in 2023 and the market decline will start in earnest. At best, the S&P 500 is range bound but headed toward the bottom of that range. The following week could be trying for the market with little to sustain the rebound regarding economic data or earnings reports. Featured: Washington's Shocking Move: Your Savings Aren't Safe Anymore (Ad) 
|
Markets | |
If you own a portfolio of dividend stocks, you might wonder how to earn more income from your investments.
You can follow one simple strategy to unlock more income from your portfolio. This strategy involves limited risk and may also lead to appreciable upside returns.
Let’s cover this st... Read the Full Story |
|
From Our Partners | | Spot the Signals Before They Become Obvious
We track early shifts in volume, structure, and emerging trends as they begin to form.
Trading Ideas focuses on data patterns that often develop before broader visibility. | | Join Free — Start Seeing the Data Early |
|
Auto/Tires/Trucks | |
It’s too soon to call October 13th the low for U.S. stocks. With the Federal Reserve steadfast in its view of higher rates for longer, equity valuations may not have yet reached the basement.
The good news is that the stock market has distanced itself from its 2022 bottom. And with some Fed... Read the Full Story |
|
Transportation | |
Oil tankers have been on an uptrend for the past year, with no real signs of slowing down. In one of the latest developments, Nordic American Tanker Ltd. (NYSE: NAT) on February 27, boosted its shareholder payout by 200%, from $0.05 a share to $0.15, according to MarketBeat data on dividend increa... Read the Full Story |
|
From Our Partners | | Every morning before the market opens, a scanner called Oracle runs through 15,000 stocks and scores the setups — so there's already a plan in place by 6:15 a.m.
Lead Trainer Tim Bohen of StocksToTrade is walking through exactly how Oracle works and how regular traders are using it in a training running right now. | | Watch the Oracle training now and see how the scanner works |
|
Technology | |
High-growth cloud computing firm Snowflake (NYSE: SNOW) reported earnings after the close on Wednesday, and the results were not what investors were hoping for. The stock dropped by 11% following the earnings report, which showed disappointing guidance.
Snowflake is one of the fastest-growing tec... Read the Full Story |
|
Consumer Staples | |
Investors who’ve shied away from Hormel (NYSE: HRL) may want to take a 2nd look. The Q1 results and guidance for 2023 have sparked a pullback in prices that should result in another stunning rebound. This stock is trading at a 2-year low which marks the bottom of the post-pandemic trading ra... Read the Full Story |
|
From Our Partners | | A couple of years ago, we started playing with the massive amounts of data that MarketBeat takes in everyday trying to figure out if there was a way to identify short term trading wins. By analyzing earnings data, news sentiment, analyst recommendations, insider transactions and dozens of other data points, we think we’ve found an algorithm that finds interesting short-term stock ideas. We call that algorithm the IdeaEngine and its stock ideas are published on MarketBeat All Access every Monday morning. We make one IdeaEngine idea available free every Monday as an SMS alert. We’ll be releasing the next IdeaEngine alert on Monday morning, so make sure you are signed up before then. | | Get MarketBeat IdeaEngine Alerts (Free) |
|
Medical | |
If you have questions about AbbVie stock, we have answers. The bottom line is that AbbVie is one of the world's leading pharmaceutical companies with one attractive dividend.
Not only is the dividend a high yield, but it is also safe and has a robust outlook for distribution increases. The quest... Read the Full Story |
|
Retail/Wholesale | |
Ross Stores Inc (NASDAQ: ROST) shares dropped as much as 5% during Wednesday's trading session, despite the discount retailer's earnings report surpassing headline expectations. It was a similar reaction to their peers at Target Corporation (NYSE: TGT), who underwhelmed investors this week despite... Read the Full Story |
|
Technology | |
If there were any doubts about Salesforce.com’s (NASDAQ: CRM) Q4 performance and outlook for 2023 they have been laid to rest. The Q4 results are so far above expectation they and the outlook have the stock up more than 15% in premarket trading and on the cusp of a complete reversal. The que... Read the Full Story |
|
Retail/Wholesale | |
Issues with the Albertson’s (NYSE: ACI) merger aside, The Kroger Co. (NYSE: KR) is one attractive stock at a critical juncture regarding price action. The price action in The Kroger Co. has corrected its pandemically-induced high and is now back in line with reality. What does that mean? Kro... Read the Full Story |
|
Construction | |
The United States housing market has experienced its largest decline since the 2008 housing crisis, causing a wave of repercussions and side effects across all markets, particularly within the lumber prices in the open market. Lumber and oriented strand board (OSB) are principal components of home... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. | | View Today's Stock Pick |
|
